

LSD-25

January 8, 1964

R. Bircher, M. D.  
Medical Director  
Sandoz Pharmaceuticals  
Hanover, New Jersey

Dear Dr. Bircher:

It has taken us a year to establish the clinical and laboratory facilities of our Institute, but now we are progressing very nicely in our psychopharmacology research program.

I am writing to request your cooperation in obtaining supplies of LSD-25 in amounts sufficient for two studies. In one, Dr. Sam Gershon, Principal Research Scientist (Pharmacology), would like to compare the antagonism of LSD to chlorpromazine, and compare this effect with the Ditrin - chlorpromazine pattern. In this study, he is continuing his assessment of a variety of blocking agents to anticholinergic compounds. The study has both clinical and EEG aspects.

Some years ago, I became interested in the effects of various drugs on electrographical slow wave activity. Dr. Turan Itil, who is on the staff of the Institute as Principal Research Scientist (EEG), has reawakened that interest by his observations of the effects of LSD on EEG patterns which is highly dependent on the initial state of the electroencephalogram. We would like to reassess this relationship.

From some of the communications which Dr. Ulett, Director of the Division of Mental Diseases, has sent to me, I am aware that there are problems in the distribution of LSD. The control of the

R. Bircher, M. D.  
January 8, 1964  
Page Two

distribution and use of LSD in the Missouri Institute of Psychiatry is vested in my office, and for this reason I am writing directly to you. I would appreciate your cooperation in providing us with about 30 ampoules of LSD, if they are still made up in 100 gamma quantities.

Dr. Ulett joins me in wishing you the best for this year.

Sincerely yours,

Max Fink, M. D.  
Director

MF:mlg